The iGreenGO Study: The Clinical Role of Indocyanine Green Imaging Fluorescence in Modifying the Surgeon's Conduct During the Surgical Treatment of Advanced Gastric Cancer-Study Protocol for an International Multicenter Prospective Study.
D2 lymphadenectomy
advanced
gastric cancer
indocyanine green (ICG)
surgery
surgical conduct
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
01
2022
accepted:
14
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
The near-infrared/indocyanine green imaging fluorescence (NIR/ICG) technology is showing promising results in several fields of surgical oncology. The clinical value of NIR/ICG technology in the surgical treatment of advanced gastric cancer (AGC) is not clearly established. This is the protocol of the "iGreenGO" (indocyanine Green Gastric Observation) Study, a national prospective multicenter study. Western patients who undergo curative-intent gastrectomy with D2 lymphadenectomy for AGC constitute the study cohort. All the patients undergo preoperative upper gastrointestinal endoscopy for submucosal peritumoral ICG injection at the most 20 h before surgery. Intraoperative endoscopic injection before starting surgical dissection is also allowed. The primary endpoint is the "change in the surgical conduct" (CSC), i.e., the need to perform further dissection after intraoperative NIR/ICG technology activation at the end of D2 lymphadenectomy. Secondary endpoints include the pattern of abdominal fluorescence distribution according to tumor and patient characteristics, the preoperative clinical variables potentially associated with CSC, and the incidence of stage migration due to NIR/ICG application. The iGreenGO Study is the first study to investigate the clinical role of NIR/ICG technology for the surgical treatment of AGC in a large cohort of Western patients. Results from the present study can further clarify the role of NIR/ICG technology in surgical lymphadenectomy for AGC.
Sections du résumé
Background
UNASSIGNED
The near-infrared/indocyanine green imaging fluorescence (NIR/ICG) technology is showing promising results in several fields of surgical oncology. The clinical value of NIR/ICG technology in the surgical treatment of advanced gastric cancer (AGC) is not clearly established.
Methods
UNASSIGNED
This is the protocol of the "iGreenGO" (indocyanine Green Gastric Observation) Study, a national prospective multicenter study. Western patients who undergo curative-intent gastrectomy with D2 lymphadenectomy for AGC constitute the study cohort. All the patients undergo preoperative upper gastrointestinal endoscopy for submucosal peritumoral ICG injection at the most 20 h before surgery. Intraoperative endoscopic injection before starting surgical dissection is also allowed. The primary endpoint is the "change in the surgical conduct" (CSC), i.e., the need to perform further dissection after intraoperative NIR/ICG technology activation at the end of D2 lymphadenectomy. Secondary endpoints include the pattern of abdominal fluorescence distribution according to tumor and patient characteristics, the preoperative clinical variables potentially associated with CSC, and the incidence of stage migration due to NIR/ICG application.
Discussion
UNASSIGNED
The iGreenGO Study is the first study to investigate the clinical role of NIR/ICG technology for the surgical treatment of AGC in a large cohort of Western patients. Results from the present study can further clarify the role of NIR/ICG technology in surgical lymphadenectomy for AGC.
Identifiants
pubmed: 35372091
doi: 10.3389/fonc.2022.854754
pmc: PMC8968043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
854754Informations de copyright
Copyright © 2022 Lombardi, Mazzola, Nicastro, Giacopuzzi, Baiocchi, Castoro, Rosati, Fumagalli Romario, Bonavina, Staderini, Gockel, Gregori, De Martini, Gualtierotti, Danieli, Beretta, Mutignani, Forti and Ferrari.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Surg. 2019 Sep;218(3):631-638
pubmed: 30712863
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
ANZ J Surg. 2006 Jan-Feb;76(1-2):75-7
pubmed: 16483302
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192
pubmed: 35130500
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
J Gastric Cancer. 2018 Jun;18(2):161-171
pubmed: 29984066
Ann Oncol. 2010 May;21 Suppl 5:v50-4
pubmed: 20555102
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Cancer Treat Rev. 2015 May;41(5):448-54
pubmed: 25814393
Gastric Cancer. 2021 Jan;24(1):258-271
pubmed: 32737637
J Surg Oncol. 2014 Dec;110(7):888-92
pubmed: 25124992
Ann Surg. 2007 Apr;245(4):543-52
pubmed: 17414602
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
JAMA Surg. 2019 Feb 1;154(2):150-158
pubmed: 30427990
Br J Surg. 2014 Sep;101(10):1209-29
pubmed: 25047143
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
Surg Today. 2020 Oct;50(10):1187-1196
pubmed: 32246228
JAMA Surg. 2020 Apr 1;155(4):300-311
pubmed: 32101269
Ann Surg. 2019 Dec;270(6):983-991
pubmed: 30829698
J Surg Oncol. 2018 Dec;118(8):1243-1256
pubmed: 30380146
Cancer Manag Res. 2018 Feb 07;10:239-248
pubmed: 29445300
World J Gastroenterol. 2018 Jul 21;24(27):2921-2930
pubmed: 30038461
Transl Gastroenterol Hepatol. 2017 Apr 07;2:28
pubmed: 28447063
Clin Pharm. 1989 Jan;8(1):54-5
pubmed: 2912666
Br J Surg. 2005 Sep;92(9):1055-6
pubmed: 16106468
Br J Surg. 2009 Nov;96(11):1289-94
pubmed: 19847873
Br J Surg. 1998 Nov;85(11):1457-9
pubmed: 9823902
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Gastric Cancer. 2016 Apr;19(2):329-338
pubmed: 26643880
Gastric Cancer. 2017 Jan;20(1):20-30
pubmed: 27255288
Gastric Cancer. 2016 Jan;19(1):15-20
pubmed: 26140915
SAGE Open Med. 2017 Aug 21;5:2050312117727444
pubmed: 28856007
J Surg Oncol. 2011 Sep 1;104(3):323-32
pubmed: 21495033
Br J Surg. 2018 Sep;105(10):1359-1367
pubmed: 29663330
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Hepatogastroenterology. 1990 Apr;37(2):223-32
pubmed: 2187787